ClinicalTrials.gg
CompletedNCT05964920Updated Mar 6, 2026

Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?

A Phase 2/3 interventional study of Saline and Testosterone Undecanoate in Healthy Aging, Age-Related Sarcopenia and Testosterone Deficiency, sponsored by Norwegian School of Sport Sciences. Completed at 1 site in Norway. Open to male participants aged 55 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Norwegian School of Sport Sciences · Phase 2/3, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
55 Years to 70 Years
Sex
Male
01

Study summary

This project's primary aim of this double-blinded, randomised, placebo-controlled trial is to investigate whether short-term testosterone administration +/- resistance exercise training induces a muscle memory response that can lead to longer-lasting benefits in aged human skeletal muscle.

The investigators will provide older men with the anabolic hormone, testosterone or placebo, with or without resistance training, followed by a period of testosterone abstinence and detraining, followed by a subsequent repeated period of resistance training (retraining). This will help determine if earlier encounters with short-term testosterone administration can be "remembered" and if adaptation to later retraining can be enhanced as a consequence of encountering testosterone earlier.

02

Conditions studied

  • Healthy Aging
  • Age-Related Sarcopenia
  • Testosterone Deficiency

Browse trials for

Keywords

  • Healthy aging
  • Preventing Age-related Sarcopenia
  • Overcoming Anabolic Resistance
  • Anti-Doping
03

In context

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

This study's enrollment of 45 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Norwegian School of Sport Sciences is the lead sponsor of 46 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sedentary males
  • 55-70 years old
  • Serum testosterone levels >8 nmol/L measured in the morning
  • Without any known illness, disease or other conditions
  • Undergone screening through medical questionnaire, physical examination, routine blood tests and urine sample
  • Written received

Exclusion criteria

Exclusion Criteria:

  • Current or previous participation in a formal exercise regime
  • A \< 18 or > 30 kg·m2
  • to the study drug or to any of its constituents
  • Active cardiovascular disease: uncontrolled hypertension (BP > 160/100 mmHg), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event
  • Family history of early (\<55y) death from cardiovascular disease
  • Haematocrit >50%
  • Prostate-specific antigen (PSA) >4 ng/mL
  • Lower urinary tract symptoms
  • Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial), epilepsy
  • Respiratory diseases including: pulmonary hypertension, chronic obstructive pulmanary disease (), asthma, sleep apnoea
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes
  • Active inflammatory bowel or renal disease
  • Current or previous treatment or hormone replacement therapy
  • Clotting dysfunction
  • Musculoskeletal or neurological disorders
  • Alcohol or drug abuse
  • Receiving oral anticoagulants
  • Serum testosterone levels above the reference range for 50 year olds (>32 nmol/L) (Bjerner et al., 2009) measured in the morning 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    The placebo group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and placebo abstinence (week 22) 4. Retraining (week 32)

    Drug: Saline

  • Experimental
    Testosterone Undecanoate

    The testosterone group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and testosterone abstinence (week 22) 4. Retraining (week 32)

    Drug: Testosterone Undecanoate

  • Placebo comparator
    Resistance exercise training + Placebo

    The resistance exercise training + placebo group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and placebo abstinence (week 22) 4. Retraining (week 32)

    Drug: Saline + Resistance exercise training

  • Experimental
    Resistance exercise training + Testosterone Undecanoate

    The resistance exercise training + testosterone group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks. Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of: 1. Baseline (week 0) 2. Treatment period (week 10) 3. Detraining and testosterone abstinence (week 22) 4. Retraining (week 32)

    Drug: Testosterone Undecanoate + Resistance exercise training

Interventions

  • DrugSaline

    Two placebo injections one at baseline and one week 3.

    Also known as: Placebo

  • Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.

    Also known as: Nebido, Grünenthal (Grünenthal Norway AS)

  • DrugSaline + Resistance exercise training

    Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.

    Also known as: Placebo + Resistance exercise training

  • DrugTestosterone Undecanoate + Resistance exercise training

    Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.

    Also known as: Nebido, Grünenthal (Grünenthal Norway AS) + Resistance exercise training

06

What researchers measure

Primary outcomes

  1. Fat-free mass

    Change and differences in fat-free mass (g) measured by dual x-ray absorptiometry (DEXA).

    Time frame: Baseline and weeks 10, 22, 32

  2. Skeletal muscle size and cross-sectional area (CSA)

    Change and differences in skeletal muscle size and CSA measured by ultrasound

    Time frame: Baseline and week 5,10, 16, 22, 27, 32

  3. Skeletal muscle fibre CSA

    Change and differences in skeletal muscle fibre CSA measure determined by immunohistochemistry

    Time frame: Baseline and weeks 10, 22, 32

Secondary outcomes

  1. DNA methylation in skeletal muscle and blood

    Methylation measured in difference/fold change values relative to appropriate controls.

    Time frame: Baseline and weeks 10, 22, 32

  2. Gene expression in skeletal muscle and blood

    Gene expression measured in difference/fold change values relative to appropriate controls.

    Time frame: Baseline and weeks 10, 22, 32

  3. Myonuclei

    Change and differences in number of myonuclei determined by immunohistochemistry

    Time frame: Baseline and weeks 10, 22, 32

  4. Satellite cells

    Change and differences in number of satellite cells determined by immunohistochemistry

    Time frame: Baseline and weeks 10, 22, 32

  5. Isometric muscle strength

    Change and differences in peak muscle strength (N) using isokinetic dynamometry

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  6. Dynamic muscle strength

    Change and differences in 1-repetition maximum

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  7. Muscle force-velocity profiling

    Change and differences in force (N) and velocity (m/s) derived from a 10-repetition FV-test

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

Other outcomes

  1. Skeletal muscle stiffness

    Change and differences in skeletal muscle stiffness measured by shear wave ultrasonography

    Time frame: Baseline and weeks 10, 22, 32

  2. Skeletal muscle tissue characteristics

    Change and differences in skeletal muscle tissue characteristics determined by immunohistochemistry of muscle biopsies

    Time frame: Baseline and weeks 10, 22, 32

  3. Bone mineral density

    Change and differences in bone mineral density (g/cm2) measured by DEXA

    Time frame: Baseline and weeks 10, 22, 32

  4. Bone health

    Change and differences in bone health determined by bone health biomarkers in blood

    Time frame: Baseline and weeks 10, 22, 32

  5. Blood volume, haemoglobin and lean body mass

    To investigate the association between blood volume, haemoglobin mass and lean body mass measured by carbon monoxide (CO) rebreathing and DEXA.

    Time frame: Baseline and weeks 10, 22, 32

  6. Blood parameters

    Change and differences in steroid hormones in blood (testosterone, androstenediol, estradiol, and other relevant steroid markers, reproductive hormones (LH, FSH), binding protein (SHBG), cholesterol (total cholesterol, LDL, HDL), and PSA level, and endocrine biomarkers (IGF-1 and P-III-NP).

    Time frame: Baseline and weeks 10, 22, 32

  7. Aging males symptoms

    Change and differences in Aging male symptoms score (1="none", 5="extremely severe")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  8. Well-being

    Change and differences in WHO5 well-being index score (0="at not time", 5="all of the time")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  9. Psychological distress

    Change and differences in SCL-10 symptoms score (1="not at all", 4="extremely")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  10. Fatigue

    Change and differences in shortened fatigue questionnaire score (1="yes, that is true", 7="no, that is not true")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  11. Sleep

    Change and differences in Jenkins sleep scale score (0="not at all", 5="22-31days")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  12. Sexual function

    Change and differences in sexual function score (items from Health-related quality of life (HRQOL) questionnaire), (

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  13. Body perception

    Change and differences in Body Perception Questionnaire very short form score (1=never, 5=always)

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  14. Anger

    Change and differences in The State Anger subscale of STAXI-2score (0="not at all", 3="very much")

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  15. Mania

    Change and differences in Altman Self-Rating Mania Scale (ASRM) score

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  16. Suicide thoughts

    Change and differences in Suicide thoughts from Montgomery and Åsberg Depression Rating Scale

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  17. Cognitive function

    Change and differences in cognitive function measured by emotion recognition tasks and cognitive reflection tasks

    Time frame: Baseline and weeks 5, 10, 16, 22, 27, 32

  18. Exercise motivation

    Change and differences in perceived motivation score and motivation type

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

  19. Exercise effort

    Change and differences in rating of perceived exertion for effort (Borg CR-10 RPE)

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

  20. Exercise discomfort

    Change and differences in rating of perceived exertion for discomfort (sRPD) score

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

  21. Session pleasure and displeasure

    Change and differences in perceived pleasure/displeasure with the training session using the pleasure/displeasure feeling scale (sPDF), (-5=very bad", 5="very good")

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

  22. Exercise enjoyment

    Change and differences in exercise enjoyment scale score (1="not at all", 7=extraordinary")

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

  23. Reps in reserve

    Change and differences in the ability to predict reps in reserve

    Time frame: Baseline and weekly up to week 10, and weekly from week 22 up to week 32

07

Study locations

1 site
  • Norwegian School of Sport Sciences
    Oslo, Oslo 0863, Norway
08

References and documents

Publications

  • Egner IM, Bruusgaard JC, Eftestol E, Gundersen K. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. J Physiol. 2013 Dec 15;591(24):6221-30. doi: 10.1113/jphysiol.2013.264457. Epub 2013 Oct 28. PubMed 24167222 ↗
  • Seaborne RA, Strauss J, Cocks M, Shepherd S, O'Brien TD, van Someren KA, Bell PG, Murgatroyd C, Morton JP, Stewart CE, Sharples AP. Human Skeletal Muscle Possesses an Epigenetic Memory of Hypertrophy. Sci Rep. 2018 Jan 30;8(1):1898. doi: 10.1038/s41598-018-20287-3. PubMed 29382913 ↗
  • Turner DC, Seaborne RA, Sharples AP. Comparative Transcriptome and Methylome Analysis in Human Skeletal Muscle Anabolism, Hypertrophy and Epigenetic Memory. Sci Rep. 2019 Mar 12;9(1):4251. doi: 10.1038/s41598-019-40787-0. PubMed 30862794 ↗
  • Sharples AP, Turner DC. Skeletal muscle memory. Am J Physiol Cell Physiol. 2023 Jun 1;324(6):C1274-C1294. doi: 10.1152/ajpcell.00099.2023. Epub 2023 May 8. PubMed 37154489 ↗
  • Gharahdaghi N, Rudrappa S, Brook MS, Idris I, Crossland H, Hamrock C, Abdul Aziz MH, Kadi F, Tarum J, Greenhaff PL, Constantin-Teodosiu D, Cegielski J, Phillips BE, Wilkinson DJ, Szewczyk NJ, Smith K, Atherton PJ. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1276-1294. doi: 10.1002/jcsm.12472. Epub 2019 Sep 30. PubMed 31568675 ↗
  • Sharples AP, Polydorou I, Hughes DC, Owens DJ, Hughes TM, Stewart CE. Skeletal muscle cells possess a 'memory' of acute early life TNF-alpha exposure: role of epigenetic adaptation. Biogerontology. 2016 Jun;17(3):603-17. doi: 10.1007/s10522-015-9604-x. Epub 2015 Sep 8. PubMed 26349924 ↗
  • Wen Y, Dungan CM, Mobley CB, Valentino T, von Walden F, Murach KA. Nucleus Type-Specific DNA Methylomics Reveals Epigenetic "Memory" of Prior Adaptation in Skeletal Muscle. Function (Oxf). 2021 Aug 5;2(5):zqab038. doi: 10.1093/function/zqab038. eCollection 2021. PubMed 34870208 ↗

Individual participant data

Plan to share: No — No identifiable information will be included in any publication. Genome-Wide DNA Methylation and Gene Expression will be deposited with full open access on Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) an internationally recognised database. GEO data derived from human samples will be anonymous, with no identifiable information. GEO data will be deposited at the same time as a publication. All non-identifiable results from the project will be ultimately published in peer-reviewed journals. In addition, all image files, raw excel/ .csv / txt /word files for any of the other analyses described above in the methods will be available as either supplementary files on the publisher's website or fully accessible on request to the corresponding author/authors.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Dec 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jul 28, 2023
StartActual
Sep 1, 2024
Primary completionActual
Dec 22, 2025
CompletionActual
Feb 6, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05964920
Lead sponsor
Norwegian School of Sport Sciences
Responsible party
Adam Sharples (Professor, Norwegian School of Sport Sciences) — Principal investigator
First posted
Jul 28, 2023
Start date
Sep 1, 2024
Primary completion
Dec 22, 2025
Completion
Feb 6, 2026
Last update
Mar 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone undecanoate

Start the discussion